Bristol Myers Squibb shares surge 6.5% on successful Phase 3 clinical trial results
BMY Bristol-Myers Squibb Co
$59.12 -0.77%
View chart & analysis → 
- 1Bristol Myers Squibb shares recorded a 6.5% increase.
- 2The ACTION-1 clinical trial met its primary endpoint.
- 3The ALOFT-IPF clinical trial met its primary endpoint.
So what's the key point?
Two drug trials conducted by Bristol Myers Squibb achieved their target results. Shares rose 6.5% following this news.
Source Investing.com +2 · View original ↗
Today's 5 AI picks, all freeNothing hidden: past picks and how they did against the S&P 500.